India’s Supreme Court Stays Blockage Of Cipla Generic Sutent
This article was originally published in PharmAsia News
Executive Summary
India's Supreme Court issued a stay of a Delhi High Court that blocked Cipla's production of its sunitinib generic of Pfizer’s Sutent for treating renal cancer.